Double ART therapy of GSK demonstrated efficacy in the final stages of clinical trials
The British pharmaceutical company GlaxoSmithKline reported on Thursday that its experimental drug for HIV treatment, which is a fixed dosage of drugs dolutegravir and lamivudine (dual therapy), during the final stages of clinical trials achieved the set goals.
The GEMINI study, quoted by the Financial Times ViiV, is designed to demonstrate the promise and safety of the use of two-component therapy in the treatment of HIV infection:
"Patients can control their disease with two drugs instead of three or more. It is important to note that this regimen [dolutegravir / lamivudine, - Ed.] Can be a treatment option for most "naive" patients around the world because of their tolerability. "
As the head of ViiV Deborah Waterhouse (Deborah Waterhouse), given the results of CI, the new tool can put the company at the forefront of the new two-component model of HIV treatment, leaving behind Gilead.
The press service of ViiV Healthcare confirmed that in 2019 the company intends to submit all the necessary regulatory documentation for registration of the two-component regimen of dolutegravir / lamivudine.
Analysts predict that the successful results of the Gemini clinical trial, in which nearly 1,500 people from Europe, America, South Africa and the APR countries took part, can significantly increase the share of GSK in the antiretroviral drug market. According to some estimates, its volume can reach up to $ 20 billion a year.
In the case of the success of the two-component ARVT model by 2025, GSK's annual sales in this segment can reach 1.1 billion pounds.